FHIR Implementation Guide for NJSAMS
1.0.0 - release
1.0.0 - release
NJSAMS - Local Development build (v1.0.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Official URL: https://fhir.njsams.rutgers.edu/NJSAMS-fhir/Questionnaire/HallucinogenUseDisordersQuestionnaire | Version: 1.0.0 | |||
| Draft as of 2022-08-31 | Computable Name: | |||
Criteria for Hallucinogen Use Disorder
Generated Narrative: Questionnaire HallucinogenUseDisordersQuestionnaire
| LinkID | Text | Cardinality | Type | Description & Constraints |
|---|---|---|---|---|
  | Criteria for Hallucinogen Use Disorder | Questionnaire | https://fhir.njsams.rutgers.edu/NJSAMS-fhir/Questionnaire/HallucinogenUseDisordersQuestionnaire#1.0.0 | |
  PhenDisSymptoms | null | 0..1 | group | |
  PhenDisSymptoms.301 | 301. Phencyclidine is often taken in larger amounts or over a longer period than was intended | 0..1 | boolean | |
| PhenDisSymptoms.302 | 302. There is a persistent desire or unsuccessful efforts to cut down or control phencyclidine use. | 0..1 | boolean | |
| PhenDisSymptoms.303 | 303. A great deal of time is spent in activities necessary to obtain phencyclidine, use phencyclidine, or recover from its effects. | 0..1 | boolean | |
| PhenDisSymptoms.304 | 304. Craving, or a strong desire or urge to use phencyclidine. | 0..1 | boolean | |
| PhenDisSymptoms.305 | 305. Recurrent phencyclidine use resulting in a failure to fulfill major role obligations at work, school, or home [e.g., repeated absences from work or poor work performance related to hallucinogen use; phencyclidine-related absences, suspensions, or expulsions from school; neglect of children or household]. | 0..1 | boolean | |
| PhenDisSymptoms.306 | 306. Continued phencyclidine use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of phencyclidine [e.g., arguments with a spouse about consequences of intoxication; physical fights]. | 0..1 | boolean | |
| PhenDisSymptoms.307 | 307. Important social, occupational, or recreational activities are given up or reduced because of phencyclidine. | 0..1 | boolean | |
| PhenDisSymptoms.308 | 308. Recurrent phencyclidine use in situations in which it is physically hazardous [e.g., driving an automobile or operating a machine when impaired by phencyclidine]. | 0..1 | boolean | |
| PhenDisSymptoms.309 | 309. Phencyclidine use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by phencyclidine. | 0..1 | boolean | |
 Tolerance | Tolerance, as defined by either of the following: | 0..1 | group | |
 PhenDisSymptoms.Tolerance.311 | 311. A need for markedly increased amounts of phencyclidine to achieve intoxication or desired effect. | 0..1 | boolean | |
| PhenDisSymptoms.Tolerance.312 | 312. A markedly diminished effect with continued use of the same amount of phencyclidine. | 0..1 | boolean | |
| OtherHallucinogenUseDisorder | null | 0..1 | group | |
| OtherHallucinogenUseDisorder.351 | 351. The hallucinogen is often taken in larger amounts or over a longer period than was intended | 0..1 | boolean | |
| OtherHallucinogenUseDisorder.352 | 352. There is a persistent desire or unsuccessful efforts to cut down or control hallucinogen use. | 0..1 | boolean | |
| OtherHallucinogenUseDisorder.353 | 353. A great deal of time is spent in activities necessary to obtain the hallucinogen, use the hallucinogen, or recover from its effects | 0..1 | boolean | |
| OtherHallucinogenUseDisorder.354 | 354. Craving, or a strong desire or urge to use the hallucinogen. | 0..1 | boolean | |
| OtherHallucinogenUseDisorder.355 | 355. Recurrent hallucinogen use resulting in a failure to fulfill major role obligations at work, school, or home [e.g., repeated absences from work or poor work performance related to hallucinogen use; hallucinogen-related absences, suspensions, or expulsions from school; neglect of children or household]. | 0..1 | boolean | |
| OtherHallucinogenUseDisorder.356 | 356. Continued hallucinogen use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the hallucinogen [e.g., arguments with a spouse about consequences of intoxication; physical fights]. | 0..1 | boolean | |
| OtherHallucinogenUseDisorder.357 | 357. Important social, occupational, or recreational activities are given up or reduced because of hallucinogen use. | 0..1 | boolean | |
| OtherHallucinogenUseDisorder.358 | 358. Recurrent hallucinogen use in situations in which it is physically hazardous [e.g., driving an automobile or operating a machine when impaired by the hallucinogen] | 0..1 | boolean | |
| OtherHallucinogenUseDisorder.359 | 359. Hallucinogen use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the hallucinogen | 0..1 | boolean | |
| Tolerance | Tolerance, as defined by either of the following: | 0..1 | group | |
| OtherHallucinogenUseDisorder.Tolerance.361 | 361. A need for markedly increased amounts of the hallucinogen to achieve intoxication or desired effect. | 0..1 | boolean | |
| OtherHallucinogenUseDisorder.Tolerance.361 | 362. A markedly diminished effect with continued use of the same amount of the hallucinogen | 0..1 | boolean | |
| PhenIntoxSymptoms | null | 0..1 | group | |
| PhenIntoxSymptoms.375 | 375. A. Recent use of phencyclidine[or a pharmacologically similar substance]. | 0..1 | boolean | |
| PhenIntoxSymptoms.376 | 376. B. Clinically significant problematic behavioral changes[e.g.,belligerence, assaultiveness, impulsiveness, unpredictability, psychomotor agitation, impaired judgement] that developed during, or shortly after, phencyclidine use. | 0..1 | boolean | |
| SignsOrSymptoms | C. Within 1 hour, two (or more) of the following signs or symptoms: Note: When the drug is smoked, snorted, or used intravenously, the onset may be particularly rapid. | 0..1 | group | |
| PhenIntoxSymptoms.SignsOrSymptoms.378 | 378. Vertical or horizontal nystagmus | 0..1 | boolean | |
| PhenIntoxSymptoms.SignsOrSymptoms.379 | 379. Hypertension or tachycardia | 0..1 | boolean | |
| PhenIntoxSymptoms.SignsOrSymptoms.380 | 380. Numbness or diminished responsiveness to pain | 0..1 | boolean | |
| PhenIntoxSymptoms.SignsOrSymptoms.381 | 381. Ataxia | 0..1 | boolean | |
| PhenIntoxSymptoms.SignsOrSymptoms.382 | 382. Muscle rigidity | 0..1 | boolean | |
| PhenIntoxSymptoms.SignsOrSymptoms.383 | 383. Seizures or coma | 0..1 | boolean | |
| PhenIntoxSymptoms.SignsOrSymptoms.384 | 384. Hyperacusis | 0..1 | boolean | |
| PhenIntoxSymptoms.385 | 385. D. The signs or symptoms are not attributable to another medical condition and are not better explained by another mental disorder, including intoxication with another substance. | 0..1 | boolean | |
| OtherHallucinogenIntoxication | null | 0..1 | group | |
| OtherHallucinogenIntoxication.325 | 325. A. Recent use of hallucinogen[other than phencyclidine]. | 0..1 | boolean | |
| OtherHallucinogenIntoxication.326 | 326. B. Clinically significant problematic behavioral or psychological changes[e.g.,marked anxiety or depression,ideas of reference, fear or losing ones mind , paranoid ideation, impaired judgement that developed during, or shortly after, hallucinogen use.] | 0..1 | boolean | |
| OtherHallucinogenIntoxication.327 | 327. C. Perceptual changes occurring in a state of full wakefulness and sonalization, derealization, illusions, hallucinations, synesthesias that developed during or shortly after, hallucinogen use. | 0..1 | boolean | |
| SignsOrSymptoms | D. Two (or more) of the following signs developing during, or shortly after, hallucinogen use: | 0..1 | group | |
| OtherHallucinogenIntoxication.SignsOrSymptoms.329 | 329. Pupillary dilation | 0..1 | boolean | |
| OtherHallucinogenIntoxication.SignsOrSymptoms.330 | 330. Tachycardia | 0..1 | boolean | |
| OtherHallucinogenIntoxication.SignsOrSymptoms.331 | 331. Sweating | 0..1 | boolean | |
| OtherHallucinogenIntoxication.SignsOrSymptoms.332 | 332. Palpitations | 0..1 | boolean | |
| OtherHallucinogenIntoxication.SignsOrSymptoms.333 | 333. Blurring of vision | 0..1 | boolean | |
| OtherHallucinogenIntoxication.SignsOrSymptoms.334 | 334. Tremors | 0..1 | boolean | |
| OtherHallucinogenIntoxication.SignsOrSymptoms.335 | 335. Incoordination. | 0..1 | boolean | |
| OtherHallucinogenIntoxication.336 | 336. E. The signs or symptoms are not attributable to another medical condition and are not better explained by another mental disorder, including intoxication with another substance. | 0..1 | boolean | |
| HalluPersistPercepSymptoms | null | 0..1 | group | |
| HalluPersistPercepSymptoms.390 | 390. Following cessation of use of a hallucinogen, the reexperiencing of one or more of the perceptual symptoms that were experienced while intoxicated with the hallucinogen [e.g., geometric hallucinations, false perceptions of movement in the peripheral visual fields, flashes of color, intensified colors, trails of images of moving objects, positive afterimages, halos around objects, macropsia, and micropsia]. | 0..1 | boolean | |
| HalluPersistPercepSymptoms.391 | 391. The symptoms in Criterion A cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. | 0..1 | boolean | |
| HalluPersistPercepSymptoms.392 | 392. The symptoms are not attributable to another medical condition [e.g., anatomical lesions and infections of the brain, visual epilepsies] and are not better explained by another mental disorder [e.g., delirium major neurocognitive disorder, schizophrenia] or hypnopompic hallucinations. | 0..1 | boolean | |
| PhenUnspecifiedSymptoms | null | 0..1 | group | |
| PhenUnspecifiedSymptoms.395 | 395. This category applies to presentations in which symptoms characteristic of an phencyclidine-related disorder that cause clinically significant distress or impairment in social, occupational, or other important areas of functioning predominate but do not meet the full criteria for any specific phencyclidine-related disorder or any of the disorders in the substance-related and addictive disorders diagnostic class. | 0..1 | boolean | |
| HalluUnspecifiedSymptoms | null | 0..1 | group | |
| HalluUnspecifiedSymptoms.396 | 396. This category applies to presentations in which symptoms characteristic of an hallucinogen-related disorder that cause clinically significant distress or impairment in social, occupational, or other important areas of functioning predominate but do not meet the full criteria for any specific hallucinogen-related disorder or any of the disorders in the substance-related and addictive disorders diagnostic class. | 0..1 | boolean | |
| meetsPhenIntoxCriteria | null | 0..1 | group | |
| meetsPhenIntoxCriteria.1 | Meets Criteria for Phencyclidine Intoxication Diagnosis? | 0..1 | boolean | |
| meetsHalluIntoxCriteria | null | 0..1 | group | |
| meetsHalluIntoxCriteria.1 | Meets Criteria for Hallucinogen Intoxication Diagnosis? | 0..1 | boolean | |
| Documentation for this format | ||||